Sientra

Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini on August 29, 2003 and is headquartered in Santa Barbara, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Siena Holdings, Inc. operates as a holding American company that manages and operates an assisted care facility through its subsidiary. The private company is located in the US and has subsidiaries in the United States.

SANTA BARBARA, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra" or the “Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Denise Dajles as Vice President of Research & Development, effective today. In this new role, Ms. Dajles will report to Chief Executive Officer Ron Menezes and lead Sientra's R&D and medical affairs teams.

Sientra Announces Addition of Vice President of Research & Development

SANTA BARBARA, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that members of management are scheduled to participate in two upcoming virtual investor conferences.

Sientra to Participate in Upcoming Virtual Investor Conferences

Sientra, Inc. (SIEN) CEO Ron Menezes on Q1 2021 Results - Earnings Call Transcript

SANTA BARBARA, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced its financial results for the first quarter ended March 31, 2021.

Sientra Reports Record First Quarter 2021 Financial Results

Transaction Enables Sharper Focus on Company's Rapidly Growing Breast Product Business Transaction Enables Sharper Focus on Company's Rapidly Growing Breast Product Business

Sientra Announces Sale of miraDry Business to 1315 Capital

On Tuesday, May 11, Sientra (NASDAQ:SIEN) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Sientra's Earnings Outlook

The partnership builds on Sientra's safety profile by empowering surgeons with Butterfly Network's cutting-edge point-of-care ultrasound technology to screen and evaluate patients with breast implants The partnership builds on Sientra's safety profile by empowering surgeons with Butterfly Network's cutting-edge point-of-care ultrasound technology to screen and evaluate patients with breast implants

Sientra and Butterfly Network Announce Strategic Partnership to Improve Diagnostic Surveillance of Breast Implant Patients

Sientra's (SIEN) CEO Ron Menezes on Q4 2020 Results - Earnings Call Transcript

SANTA BARBARA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced its audited financial results for the fourth quarter and full year ended December 31, 2020.

Sientra Reports Fourth Quarter and Full Year 2020 Financial Results

SANTA BARBARA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Paul Little is stepping down from his position as Chief Financial Officer, Senior Vice President and Treasurer, to pursue other opportunities effective March 12, 2021. Valerie Miller, current Vice President, Corporate Controller, will serve as interim Chief Financial Officer effective upon Mr. Little's resignation as the Company completes its search for a permanent replacement.

Sientra Announces Departure of CFO and Appointment of Interim CFO

Sientra (NASDAQ:SIEN) announces its next round of earnings this Thursday, March 11. Here is Benzinga's look at Sientra's Q4 earnings report.

Sientra Earnings Preview

SANTA BARBARA, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Thursday, March 11, 2021. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

SANTA BARBARA, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced the company will be participating in the upcoming SVB Leerink 10th Annual Global Healthcare Conference. Sientra's management team is scheduled to present on Friday, February 26, 2021 at 3:40 p.m. ET.

Sientra to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Sientra Inc (NASDAQ: SIEN) prices its previously announced underwritten public offering of 5.4 million common shares at $6.75 per share, with gross proceeds of approximately $36.5 million. The offer price represents a discount of 16% from the last close of $7.99.

Sientra Raises $36.5M At 16% Discount From Last Close

SANTA BARBARA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced the pricing of its previously announced underwritten public offering. The Company will sell 5,410,628 shares of its common stock at a public offering price of $6.75 per share. The gross proceeds to Sientra, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $36.5 million. The offering is expected to close on or about February 11, 2021, subject to customary closing conditions. In addition, the Company has granted the underwriters a 30-day option to purchase up to 811,594 additional shares at the public offering price, less underwriting discounts and commissions.

Sientra Announces Pricing of Public Offering of Common Stock

SANTA BARBARA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it has commenced an underwritten public follow-on offering of its common stock to be sold by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase additional shares. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Sientra Commences Public Offering of Common Stock

The company released preliminary results for its fourth quarter.

Why Sientra Stock Is Soaring Today

Estimates highest ever Breast Products segment net sales of $17.9 million, representing 40% year over year growth

Sientra Reports Preliminary Fourth Quarter and Full Year 2020 Results

Sientra, Inc. (SIEN) CEO Ron Menezes on Q3 2020 Results - Earnings Call Transcript

Reports record Breast Products net sales of $15.3 million, representing 54% sequential growth and 2 1 % year over year growth

Sientra Reports Third Quarter 2020 Financial Results

Jeffrey Nugent, Current Chairman and Chief Executive Officer, Announces His Retirement

Sientra Appoints Ron Menezes as President and Chief Executive Officer

SANTA BARBARA, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Monday, November 9, 2020. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report Third Quarter 2020 Financial Results on November 9, 2020

Marks First Regulatory approval of Sientra Breast Implants Outside of the U.S. Marks First Regulatory approval of Sientra Breast Implants Outside of the U.S.

Sientra Receives Regulatory Approval to Market OPUS® Breast Implants in Japan

Aptinyx Inc

CymaBay Therapeutics

Evolus

iBio

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Red-Hot Biotech and Medtech Stocks Under $10 With Massive Upside Potential

Sientra, Inc. (SIEN) CEO Jeffrey Nugent on Q2 2020 Results - Earnings Call Transcript

News for Sientra Stock (SIEN)